Nicholas Bacopoulos
Director/Board Member at MAKScientific LLC
Nicholas Bacopoulos active positions
| Companies | Position | Start | End |
|---|---|---|---|
MAKScientific LLC
 MAKScientific LLC Pharmaceuticals: MajorHealth Technology MAKScientific LLC develops drugs to treat medical disorders by modulating the endocannabinoid system. The firm discovers medications for metabolic disorders, pain, addiction, and neurological diseases. The company was founded by Alexandros Makriyannis in 2004 and is headquartered in Mystic, CT. | Director/Board Member | - | - |
Career history of Nicholas Bacopoulos
Former positions of Nicholas Bacopoulos
| Companies | Position | Start | End |
|---|---|---|---|
| CYCLACEL PHARMACEUTICALS, INC. | Director/Board Member | 2008-09-03 | 2016-06-30 |
| Independent Dir/Board Member | 2008-09-03 | 2016-06-30 | |
Priaxon AG
 Priaxon AG Miscellaneous Commercial ServicesCommercial Services Priaxon AG operates as a drug discovery company for small molecule therapeutics. The firm develops a platform PriaXplore that consists of several chemo informatics methods and concepts especially designed for the application in the field of identifying new potential inhibitors of protein protein interactions (PPI). The company was founded by Christoph Burdack in 2008 and is headquartered in Munich, Germany. | Director/Board Member | - | - |
| Dartmouth Medical School | Corporate Officer/Principal | - | - |
| Anaderm Research Corp. | Chief Executive Officer | - | - |
| President | - | - | |
| PFIZER, INC. | Corporate Officer/Principal | - | - |
| Kotinos Pharmaceuticals, Inc. | Director/Board Member | - | - |
| OSI PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - | - |
| President | - | - | |
| Medexis Biotech SA | Director/Board Member | 2009-12-02 | - |
| Founder | - | - | |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░ ░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░░░░ | - | - |
Training of Nicholas Bacopoulos
| Cornell College (Iowa) | Undergraduate Degree |
| University of Iowa | Doctorate Degree |
Statistics
International
| United States | 12 |
| Greece | 2 |
| Germany | 2 |
Operational
| Director/Board Member | 6 |
| President | 4 |
| Chief Executive Officer | 3 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 4 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| MERSANA THERAPEUTICS, INC. | Health Technology |
| CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
Aton Pharma, Inc.
 Aton Pharma, Inc. Pharmaceuticals: MajorHealth Technology Aton Pharma, Inc. develops therapeutics for cancer and other diseases. Its products include Edecrin, Sodium Edecrin, Cuprimine, Demser and Syprine. The company was founded by Michael G. Wells in 2001 and is headquartered in Lawrenceville, NJ. | Health Technology |
| Medexis Biotech SA | |
MAKScientific LLC
MAKScientific LLC Pharmaceuticals: MajorHealth Technology MAKScientific LLC develops drugs to treat medical disorders by modulating the endocannabinoid system. The firm discovers medications for metabolic disorders, pain, addiction, and neurological diseases. The company was founded by Alexandros Makriyannis in 2004 and is headquartered in Mystic, CT. | Health Technology |
| Kotinos Pharmaceuticals, Inc. | |
| Anaderm Research Corp. | |
Priaxon AG
Priaxon AG Miscellaneous Commercial ServicesCommercial Services Priaxon AG operates as a drug discovery company for small molecule therapeutics. The firm develops a platform PriaXplore that consists of several chemo informatics methods and concepts especially designed for the application in the field of identifying new potential inhibitors of protein protein interactions (PPI). The company was founded by Christoph Burdack in 2008 and is headquartered in Munich, Germany. | Commercial Services |
- Stock Market
- Insiders
- Nicholas Bacopoulos
- Experience
